Introduction {#sec1_1}
============

The PD-1/PD-L1 pathway plays a critical role in the tumor immune response in melanoma \[[@B1], [@B2], [@B3], [@B4]\]. Nivolumab, an anti-PD-1 antibody, significantly prolonged survival in patients with metastatic melanoma, but only 30--40% of the patients who received nivolumab monotherapy experienced objective tumor regression \[[@B2], [@B5], [@B6]\]. Since nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its anti-tumor immune response is of great interest to dermato-oncologists \[[@B5], [@B7], [@B8]\]. Indeed, Weber et al. \[[@B9]\] recently reported the efficacy of sequential administration of nivolumab followed by ipilimumab and its clinical benefits.

In this report, we present a case of multiple metastatic melanomas in the lung successfully treated with nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks), but with severe liver dysfunction. Our case suggests that the anti-tumor immune response and immune-related adverse events (irAE) might develop in a dose-independent manner by immune checkpoint inhibitors.

Case Report {#sec1_2}
===========

An 80-year-old Japanese man visited our outpatient clinic with a red, easy-to-bleed nodule on his scalp. On his initial visit, physical examination revealed a red-brown, dome-shaped nodule on his scalp (fig [1a](#F1){ref-type="fig"}). A biopsy specimen revealed dense infiltration of spindle-shaped atypical cells with pigmentation from the epidermis to the deep dermis (fig [1b](#F1){ref-type="fig"}). From the above findings, we diagnosed this patient as having malignant melanoma, excised the tumor, and performed left cervical lymph node dissection. In addition, after the surgical treatment, the patient was treated with continuous administration of interferon-β (3.0 × 10^6^ U) for 10 days, once a month for 6 times, followed by the administration of interferon-β (3.0 × 10^6^ U) once a month. Two years after the surgical treatment, follow-up computed tomography (CT) revealed multiple lung metastases of melanoma (fig [2a](#F2){ref-type="fig"}), which was confirmed by exfoliative cytodiagnosis using a bronchoscope. We administered nivolumab at 2 mg/kg every 3 weeks for 12 weeks. Since follow-up CT suggested progressive lung metastasis 3 weeks after the administration of nivolumab, we sequentially administered ipilimumab at 3 mg/kg every 3 weeks. Nine weeks after the administration of ipilimumab, the serum total bilirubin level had increased to 3 times the normal range. We diagnosed the patient\'s condition as ipilimumab-induced hepatotoxicity, based on a previous report \[[@B10]\]. We intravenously administered methylprednisolone sodium succinate 1 mg/kg/day with appropriate reduction, and the serum total bilirubin level decreased to within the normal range. After the administration of methylprednisolone sodium succinate, we treated the patient with oral prednisolone 40, 35, and 30 mg/day for 1 week each. When we reduced prednisolone to 25 mg/day, the serum AST and ALT levels suddenly increased to 3 times the normal range. We intravenously administered methylprednisolone sodium succinate 1 mg/kg/day with appropriate reduction again, and the serum AST and ALT level decreased to within the normal range. After the administration of methylprednisolone sodium succinate, we treated the patient with oral prednisolone with appropriate reduction, and there was no recurrence of hepatotoxicities even when we stopped the administration of oral prednisolone. In addition, in parallel with the severe hepatotoxicities, prominent systemic vitiligo developed, suggesting the induction of anti-melanoma immune response \[[@B6]\] (fig [2b](#F2){ref-type="fig"}). Therefore, we performed a follow-up CT scan 3 months after the administration of ipilimumab during the administration of oral prednisolone for hepatitis, which revealed a prominent regression of the lung metastasis (fig [2a](#F2){ref-type="fig"}).

Discussion {#sec1_3}
==========

We describe a case of multiple metastatic melanomas in the lung successfully treated with a complete response using sequential therapy of nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks). In addition, in parallel with severe hepatotoxicities, prominent systemic vitiligo developed, which suggested the induction of anti-melanoma immune response \[[@B6]\]. Indeed, although we stopped immunotherapy for 3 months to treat the immunotherapy-induced hepatitis, the metastatic melanomas in the lung showed dramatic reduction in the tumor mass during the administration of methylprednisolone sodium succinate. Our case suggests that nivolumab followed by ipilimumab strongly induced an anti-melanoma immune response with severe irAE.

Immune checkpoint inhibitors, such as nivolumab and ipilimumab, significantly prolong the overall survival and response rate of unresectable metastatic melanoma \[[@B2], [@B5]\]. Indeed, Larkin et al. \[[@B5]\] reported that the response rate of nivolumab for unresectable metastatic melanoma is 33.7% and that of ipilimumab 19.0%. Moreover, combined nivolumab and ipilimumab significantly improved the response rate (57.9%), and this method is one of the most effective protocols for unresectable metastatic melanoma with or without *BRAF* mutation, though the ratio of irAE was also significantly increased. In addition, more recently, Weber et al. \[[@B9]\] reported that the anti-tumor efficacy of sequential administration of nivolumab (3 mg/kg every 2 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 12 weeks) is superior to its reverse sequence. Notably, they also reported that there was no significant difference in the rate of treatment-related grade 3--5 adverse events in each group \[[@B10]\], suggesting that nivolumab followed by ipilimumab is a clinically more beneficial option compared to the reverse sequence \[[@B9]\].

Since nivolumab is IgG4, which has a half-life of 3 weeks in the blood, we administered nivolumab at a dose of 2 mg/kg 4 times every 3 weeks, suggesting that an appropriate dose of nivolumab remained in the blood when we first administered ipilimumab at a dose of 3 mg/kg. Unexpectedly, despite the fact that the blood concentration of nivolumab was lower compared with previous reports \[[@B5], [@B9]\], our case developed bimodal severe hepatitis. Moreover, although we stopped the administration of nivolumab and ipilimumab during the administration of methylprednisolone sodium succinate followed by prednisolone, the melanoma in the lung decreased dramatically, suggesting that a long-term, continuous anti-melanoma immune response was induced by this sequential therapy. Our case suggested that development of an anti-tumor immune response and irAE by the immune checkpoint inhibitor might develop in a dose-independent manner. Since this report presents only a single case, further cases may provide fundamental insights into the mechanisms of immune checkpoint inhibitor-induced anti-tumor immune response and irAE.
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![**a** A red-brown, dome-shaped nodule on the scalp. **b** Dense infiltration of spindle-shaped atypical cells with pigmentation from the epidermis to the deep dermis.](cro-0009-0644-g01){#F1}

![**a** Multiple lung metastases of melanoma before and after sequential therapy. **b** Prominent, multiple vitiligo developed on the face after sequential therapy.](cro-0009-0644-g02){#F2}
